The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 3 KEYNOTE-042 trial of pembrolizumab (MK-3475) versus platinum doublet chemotherapy in treatment-naive patients (pts) with PD-L1–positive advanced non-small cell lung cancer (NSCLC).
 
Tony Mok
Employment - The Chinese University of Hong Kong
Honoraria - Amgen; AstraZeneca; AVEO; Biomarin; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Eisai; Janssen; Lilly; Merck Serono; Novartis; Pfizer; Roche/Genentech; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; AstraZeneca; AVEO; Biomarin; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Eisai; Janssen; Lilly; Merck Serono; Novartis; Pfizer; Roche/Genentech; Taiho Pharmaceutical
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Lilly; Merck Serono; Pfizer; Roche
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Boehringer Ingelheim; Lilly; Merck Serono; Pfizer; Roche
 
Yi-Long Wu
No Relationships to Disclose
 
Patricia A, Watson
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Jin Zhang
Employment - Merck
 
Reshma A. Rangwala
Employment - GlaxoSmithKline; Merck
Stock and Other Ownership Interests - Merck
 
Gilberto Lopes
Honoraria - AstraZeneca; Fresenius Kabi; Merck Serono; Merck Sharp & Dohme; Novartis; Roche/Genentech
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly/ImClone; Pfizer
Research Funding - AstraZeneca; Eisai; Lilly/ImClone; Merck Sharp & Dohme; Pfizer
Expert Testimony - Sanofi